Safety and Efficacy Study of Virus Activated Killer Immune Cells (VAK) for Malignant Pleural and Peritoneal Effusion
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
Theory of VAK：
1. Immune cells (T cells for example) of cancer subjects may be domesticated by the tumor
microenvironment, and have low efficacy to kill cancer cells. They could be restimulated
by virus antigen, and play a powerful tumor killing role while intrapleural to subjects.
2. Releasing of tumor-associated antigen could induce specific anti-tumor immune response.
Preparation of VAK：
1. Separate the immune cells and tumor cells from Malignant Pleural and Peritoneal
Effusion.
2. Incubate the immune cells with inactivated viruses and tumor cells.
3. Wash to remove impurities.
4. Intrapleural the immune cells to patients